Curation
PascalFrancis
Racine
Curation
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Epigenetic programming of neurodegenerative diseases by an adverse environment

Identifieur interne : 000A36 ( PascalFrancis/Curation ); précédent : 000A35; suivant : 000A37

Epigenetic programming of neurodegenerative diseases by an adverse environment

Auteurs : Olena Babenko [Canada] ; Igor Kovalchuk [Canada] ; Gerlinde A. Metz [Canada]

Source :

RBID : Pascal:12-0152281

Descripteurs français

English descriptors

Abstract

Experience and environment can critically influence the risk and progression of neurodegenerative disorders. Epigenetic mechanisms, such as miRNA expression, DNA methylation, and histone modifications, readily respond to experience and environmental factors. Here we propose that epigenetic regulation of gene expression and environmental modulation thereof may play a key role in the onset and course of common neurological conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. For example, epigenetic mechanisms may mediate long-term responses to adverse experience, such as stress, to affect disease susceptibility and the course of neurodegenerative events. This review introduces the epigenetic components and their possible role in mediating neuropathological processes in response to stress. We argue that epigenetic modifications will affect neurodegenerative events through altered gene function. The study of epigenetic states in neurodegenerative diseases presents an opportunity to gain new insights into risk factors and pathogenic mechanisms. Moreover, research into epigenetic regulation of disease may revolutionize health care by opening new avenues of personalized, preventive and curative medicine.
pA  
A01 01  1    @0 0006-8993
A02 01      @0 BRREAP
A03   1    @0 Brain res.
A05       @2 1444
A08 01  1  ENG  @1 Epigenetic programming of neurodegenerative diseases by an adverse environment
A11 01  1    @1 BABENKO (Olena)
A11 02  1    @1 KOVALCHUK (Igor)
A11 03  1    @1 METZ (Gerlinde A.)
A14 01      @1 Department of Biological Sciences, University of Lethbridge @2 Lethbridge, Alberta @3 CAN @Z 1 aut. @Z 2 aut.
A14 02      @1 Canadian Centre for Behavioural Neuroscience, University of Lethbridge @2 Lethbridge, Alberta @3 CAN @Z 1 aut. @Z 3 aut.
A20       @1 96-111
A21       @1 2012
A23 01      @0 ENG
A43 01      @1 INIST @2 12895 @5 354000508472020110
A44       @0 0000 @1 © 2012 INIST-CNRS. All rights reserved.
A45       @0 5 p.1/4
A47 01  1    @0 12-0152281
A60       @1 P
A61       @0 A
A64 01  1    @0 Brain research
A66 01      @0 NLD
C01 01    ENG  @0 Experience and environment can critically influence the risk and progression of neurodegenerative disorders. Epigenetic mechanisms, such as miRNA expression, DNA methylation, and histone modifications, readily respond to experience and environmental factors. Here we propose that epigenetic regulation of gene expression and environmental modulation thereof may play a key role in the onset and course of common neurological conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. For example, epigenetic mechanisms may mediate long-term responses to adverse experience, such as stress, to affect disease susceptibility and the course of neurodegenerative events. This review introduces the epigenetic components and their possible role in mediating neuropathological processes in response to stress. We argue that epigenetic modifications will affect neurodegenerative events through altered gene function. The study of epigenetic states in neurodegenerative diseases presents an opportunity to gain new insights into risk factors and pathogenic mechanisms. Moreover, research into epigenetic regulation of disease may revolutionize health care by opening new avenues of personalized, preventive and curative medicine.
C02 01  X    @0 002B17G
C02 02  X    @0 002B18C13
C03 01  X  FRE  @0 Epigenèse @5 01
C03 01  X  ENG  @0 Epigenesis @5 01
C03 01  X  SPA  @0 Epigénesis @5 01
C03 02  X  FRE  @0 Stress @5 02
C03 02  X  ENG  @0 Stress @5 02
C03 02  X  SPA  @0 Estrés @5 02
C03 03  X  FRE  @0 Micro ARN @5 03
C03 03  X  ENG  @0 Micro RNA @5 03
C03 03  X  SPA  @0 Micro ARN @5 03
C03 04  X  FRE  @0 Méthylation @5 04
C03 04  X  ENG  @0 Methylation @5 04
C03 04  X  SPA  @0 Metilación @5 04
C03 05  X  FRE  @0 Maladie de Parkinson @2 NM @5 05
C03 05  X  ENG  @0 Parkinson disease @2 NM @5 05
C03 05  X  SPA  @0 Parkinson enfermedad @2 NM @5 05
C03 06  X  FRE  @0 Chorée de Huntington @5 06
C03 06  X  ENG  @0 Huntington disease @5 06
C03 06  X  SPA  @0 Corea Huntington @5 06
C03 07  X  FRE  @0 Sclérose en plaques @2 NM @5 07
C03 07  X  ENG  @0 Multiple sclerosis @2 NM @5 07
C03 07  X  SPA  @0 Esclerosis en placa @2 NM @5 07
C03 08  X  FRE  @0 Maladie dégénérative @5 09
C03 08  X  ENG  @0 Degenerative disease @5 09
C03 08  X  SPA  @0 Enfermedad degenerativa @5 09
C03 09  X  FRE  @0 Démence d'Alzheimer @5 12
C03 09  X  ENG  @0 Alzheimer disease @5 12
C03 09  X  SPA  @0 Demencia Alzheimer @5 12
C03 10  X  FRE  @0 Article synthèse @5 57
C03 10  X  ENG  @0 Review @5 57
C03 10  X  SPA  @0 Artículo síntesis @5 57
C07 01  X  FRE  @0 Silence expression génique
C07 01  X  ENG  @0 Gene silencing
C07 01  X  SPA  @0 Silencio expresión genética
C07 02  X  FRE  @0 Pathologie du système nerveux @5 20
C07 02  X  ENG  @0 Nervous system diseases @5 20
C07 02  X  SPA  @0 Sistema nervioso patología @5 20
C07 03  X  FRE  @0 Pathologie de l'encéphale @5 21
C07 03  X  ENG  @0 Cerebral disorder @5 21
C07 03  X  SPA  @0 Encéfalo patología @5 21
C07 04  X  FRE  @0 Pathologie du système nerveux central @5 22
C07 04  X  ENG  @0 Central nervous system disease @5 22
C07 04  X  SPA  @0 Sistema nervosio central patología @5 22
C07 05  X  FRE  @0 Syndrome extrapyramidal @5 23
C07 05  X  ENG  @0 Extrapyramidal syndrome @5 23
C07 05  X  SPA  @0 Extrapiramidal síndrome @5 23
C07 06  X  FRE  @0 Maladie héréditaire @5 24
C07 06  X  ENG  @0 Genetic disease @5 24
C07 06  X  SPA  @0 Enfermedad hereditaria @5 24
C07 07  X  FRE  @0 Maladie inflammatoire @5 25
C07 07  X  ENG  @0 Inflammatory disease @5 25
C07 07  X  SPA  @0 Enfermedad inflamatoria @5 25
N21       @1 114

Links toward previous steps (curation, corpus...)

Links to Exploration step

Pascal:12-0152281

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Epigenetic programming of neurodegenerative diseases by an adverse environment</title>
<author>
<name sortKey="Babenko, Olena" sort="Babenko, Olena" uniqKey="Babenko O" first="Olena" last="Babenko">Olena Babenko</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Biological Sciences, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Canadian Centre for Behavioural Neuroscience, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author>
<name sortKey="Kovalchuk, Igor" sort="Kovalchuk, Igor" uniqKey="Kovalchuk I" first="Igor" last="Kovalchuk">Igor Kovalchuk</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Biological Sciences, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author>
<name sortKey="Metz, Gerlinde A" sort="Metz, Gerlinde A" uniqKey="Metz G" first="Gerlinde A." last="Metz">Gerlinde A. Metz</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Canadian Centre for Behavioural Neuroscience, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">12-0152281</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0152281 INIST</idno>
<idno type="RBID">Pascal:12-0152281</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000216</idno>
<idno type="stanalyst">FRANCIS 12-0152281 INIST</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000260</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000A36</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Epigenetic programming of neurodegenerative diseases by an adverse environment</title>
<author>
<name sortKey="Babenko, Olena" sort="Babenko, Olena" uniqKey="Babenko O" first="Olena" last="Babenko">Olena Babenko</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Biological Sciences, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Canadian Centre for Behavioural Neuroscience, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author>
<name sortKey="Kovalchuk, Igor" sort="Kovalchuk, Igor" uniqKey="Kovalchuk I" first="Igor" last="Kovalchuk">Igor Kovalchuk</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Biological Sciences, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author>
<name sortKey="Metz, Gerlinde A" sort="Metz, Gerlinde A" uniqKey="Metz G" first="Gerlinde A." last="Metz">Gerlinde A. Metz</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Canadian Centre for Behavioural Neuroscience, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Brain research</title>
<title level="j" type="abbreviated">Brain res.</title>
<idno type="ISSN">0006-8993</idno>
<imprint>
<date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Brain research</title>
<title level="j" type="abbreviated">Brain res.</title>
<idno type="ISSN">0006-8993</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Alzheimer disease</term>
<term>Degenerative disease</term>
<term>Epigenesis</term>
<term>Huntington disease</term>
<term>Methylation</term>
<term>Micro RNA</term>
<term>Multiple sclerosis</term>
<term>Parkinson disease</term>
<term>Review</term>
<term>Stress</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Epigenèse</term>
<term>Stress</term>
<term>Micro ARN</term>
<term>Méthylation</term>
<term>Maladie de Parkinson</term>
<term>Chorée de Huntington</term>
<term>Sclérose en plaques</term>
<term>Maladie dégénérative</term>
<term>Démence d'Alzheimer</term>
<term>Article synthèse</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Experience and environment can critically influence the risk and progression of neurodegenerative disorders. Epigenetic mechanisms, such as miRNA expression, DNA methylation, and histone modifications, readily respond to experience and environmental factors. Here we propose that epigenetic regulation of gene expression and environmental modulation thereof may play a key role in the onset and course of common neurological conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. For example, epigenetic mechanisms may mediate long-term responses to adverse experience, such as stress, to affect disease susceptibility and the course of neurodegenerative events. This review introduces the epigenetic components and their possible role in mediating neuropathological processes in response to stress. We argue that epigenetic modifications will affect neurodegenerative events through altered gene function. The study of epigenetic states in neurodegenerative diseases presents an opportunity to gain new insights into risk factors and pathogenic mechanisms. Moreover, research into epigenetic regulation of disease may revolutionize health care by opening new avenues of personalized, preventive and curative medicine.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0006-8993</s0>
</fA01>
<fA02 i1="01">
<s0>BRREAP</s0>
</fA02>
<fA03 i2="1">
<s0>Brain res.</s0>
</fA03>
<fA05>
<s2>1444</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG">
<s1>Epigenetic programming of neurodegenerative diseases by an adverse environment</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>BABENKO (Olena)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>KOVALCHUK (Igor)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>METZ (Gerlinde A.)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Biological Sciences, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Canadian Centre for Behavioural Neuroscience, University of Lethbridge</s1>
<s2>Lethbridge, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA20>
<s1>96-111</s1>
</fA20>
<fA21>
<s1>2012</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>12895</s2>
<s5>354000508472020110</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>5 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>12-0152281</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Brain research</s0>
</fA64>
<fA66 i1="01">
<s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Experience and environment can critically influence the risk and progression of neurodegenerative disorders. Epigenetic mechanisms, such as miRNA expression, DNA methylation, and histone modifications, readily respond to experience and environmental factors. Here we propose that epigenetic regulation of gene expression and environmental modulation thereof may play a key role in the onset and course of common neurological conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. For example, epigenetic mechanisms may mediate long-term responses to adverse experience, such as stress, to affect disease susceptibility and the course of neurodegenerative events. This review introduces the epigenetic components and their possible role in mediating neuropathological processes in response to stress. We argue that epigenetic modifications will affect neurodegenerative events through altered gene function. The study of epigenetic states in neurodegenerative diseases presents an opportunity to gain new insights into risk factors and pathogenic mechanisms. Moreover, research into epigenetic regulation of disease may revolutionize health care by opening new avenues of personalized, preventive and curative medicine.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B18C13</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Epigenèse</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Epigenesis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Epigénesis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Stress</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Stress</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Estrés</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Micro ARN</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Micro RNA</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Micro ARN</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Méthylation</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Methylation</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Metilación</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Chorée de Huntington</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Huntington disease</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Corea Huntington</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Sclérose en plaques</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Multiple sclerosis</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Esclerosis en placa</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Démence d'Alzheimer</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Alzheimer disease</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Demencia Alzheimer</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Article synthèse</s0>
<s5>57</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Review</s0>
<s5>57</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Artículo síntesis</s0>
<s5>57</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Silence expression génique</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Gene silencing</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Silencio expresión genética</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Pathologie du système nerveux</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>20</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Pathologie de l'encéphale</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>21</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Pathologie du système nerveux central</s0>
<s5>22</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>22</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>22</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Syndrome extrapyramidal</s0>
<s5>23</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>23</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>23</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Maladie héréditaire</s0>
<s5>24</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Genetic disease</s0>
<s5>24</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Enfermedad hereditaria</s0>
<s5>24</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Maladie inflammatoire</s0>
<s5>25</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Inflammatory disease</s0>
<s5>25</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Enfermedad inflamatoria</s0>
<s5>25</s5>
</fC07>
<fN21>
<s1>114</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A36 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000A36 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:12-0152281
   |texte=   Epigenetic programming of neurodegenerative diseases by an adverse environment
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022